13F filing recap · Q4 2024
What did Sound Shore Management buy in Q4 2024?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every Sound Shore account, including accounts that belong to no fund below.
Stock value
$3.03B
Positions
40
Estimated turnover
57.0%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Sound Shore Management opened new positions in Citigroup, Southwest Airlines, Zimmer Biomet, Bristol-Myers Squibb, Baxter International, Aes Corp, Csx Corporation, Eog Resources, and Match Group. The firm exited Elevance Health, CVS Health, Cardinal Health, Centene, Huntington Ingalls, Kraft Heinz, Merck, Oracle, and Pfizer. It substantially increased Nxp Semiconductors, Check Point Software, Incyte, and Newmont, while substantially reducing Vistra, Kinder Morgan, and General Motors.